What does Trump's decision to leave the WHO mean for public health? And should U.S. companies be intimidated by Chinese drug ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

The desire of digital health companies to scale through mergers and acquisitions or partnerships was one of the most ...

Healthcare leaders shared insights on various topics, including industry challenges, a new administration and growing their ...

Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on ...

Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for ...

The 43 rd Annual Healthcare J.P. Morgan Healthcare Conference kicked off in San Francisco, California earlier this week. Notable executives from analytical science companies were invited to speak ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...